Can ibogaine help with Parkinson's disease?

Noribogaine, the substance into which ibogaine is converted in the body, showed something striking in laboratory and fruit fly experiments: it was able to repair certain misfolded proteins in dopamine cells. Those proteins play a role in a rare, early-onset form of parkinsonism. This worked for two of the three tested variants; with the third it did not work, and noribogaine even caused fatal toxicity in the flies. These are early experiments with no human data.

For the form of Parkinson's disease that most people are familiar with, there is no clinical research involving ibogaine whatsoever. Moreover, ibogaine's mechanism of action targets primarily the serotonin system in the brain, not the dopamine deficiency that is the very core of Parkinson's disease. A direct biological link is therefore largely absent.

What is clear are the safety risks. Ibogaine inhibits potassium channels in the heart, which can lead to a dangerously prolonged heart rhythm, cardiac arrhythmias, and in some cases death. In the medical literature, 27 fatalities have been reported, including in people with no previously known heart disease. In rats, ibogaine also caused brain damage in the cerebellum at higher doses -- the part of the brain that controls movement coordination.

For Parkinson's patients there is an additional risk: they typically use several medications at the same time. Ibogaine is broken down in the body via a liver enzyme that also processes much of the medication used for Parkinson's disease. This can cause ibogaine concentrations in the blood to rise to dangerously high levels. This makes self-medication outside a clinical setting particularly risky.